Table 3.
Ages of patients with positive ASCA, GAB, PAB, and ANCA.
| Antibodies | Median (IQR), y | P value | |
|---|---|---|---|
| Female | Male | ||
| ASCA IgG | 47.0 (27.0-65.0) | 35.0 (23.0-62.0) | 0.1099 |
| ASCA IgA | 52.0 (27.5-66.5) | 40.0 (21.0-61.0) | 0.0354 |
| GAB IgG | 38.0 (27.0-53.5) | 36.0 (26.0-52.5) | 0.2218 |
| GAB IgA | 32.0 (25.0-47.5) | 31.0 (22.0-50.0) | 0.7949 |
| PAB IgG | 27.5 (22.0-37.3) | 27.5 (21.0-34.0) | 0.3483 |
| PAB IgA | 25.0 (19.0-36.0) | 28.0 (20.0-32.0) | 0.9736 |
| ANCA IgG | 48.0 (33.3-58.8) | 40.0 (29.0-52.5) | 0.0728 |
| ANCA IgA | 47.0 (33.5-61.0) | 40.0 (29.0-52.5) | 0.1035 |
Data were expressed as median (IQR) and calculated by Mann–Whitney test. IQR: interquartile range; ASCA: anti-Saccharomyces cerevisiae antibodies; GAB: anti-intestinal goblet cell antibodies; PAB: antibodies to exocrine pancreas; ANCA: anti-neutrophil cytoplasmic antibodies; IBD: inflammatory bowel disease. P values indicate differences between female and male patients. P < 0.05 was considered statistically significant.